G+Flas Life Sciences

Based in Seoul, South Korea, and founded in 2014, G+Flas Life Sciences, Inc develops new protein drugs for rare genetic diseases using gene scissors technology. In 2014, the company started joint research with Seoul National University’s Next-Generation Convergence Technology Institute and established a US subsidiary company called Naturegenic Inc. G+Flas Life Sciences, Inc has conducted joint research with KBP, a global leader in the production of Ebola antibodies in the United States, conducted joint research with NOMAD, a global leader in plant-based protein expression systems, and established its branch in Gplus Osong Gene Scissor New Drug Research Center in Cheombok Complex. The company develops CRISPR, a gene scissors technology, CRISPR PLUS, Genetic scissors design technology that maximizes the accuracy and editing efficiency of CRISPR gene scissors, Cancerase, a CRISPR anticancer drug platform, PDB Platform or Plant-derived Biopharmaceuticals Platform, a biopharmaceutical production system applied with glycoengineering technology, and Non-GMO CRISPR Healthy Seeds, a Non-GMO Glyco-engineering technology.

1. Series C

   Aug 22, 2019

   Amount

   $9.9M

   Investors

   Locked

2. Series B

   Jul 19, 2018

   Amount

   $12M

   Investors

   Locked

3. Series A

   Mar 31, 2017

   Amount

   $3.8M

   Investors

   Locked